



## Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

May 13, 2024

NASHVILLE, Tenn.--(BUSINESS WIRE)--May 13, 2024-- Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market-leading compounded division.

DiPasquale joins Harrow from Regeneron Pharmaceuticals, Inc., where he served as National Business Director and was responsible for key account management and national sales of the anti-VEGF products EYLEA® and EYLEA® HD for its two highest volume indications. Under his leadership, sales of products under Greg's portfolio grew from \$4.5 billion to over \$6 billion during a four-year period. Prior to this role, DiPasquale was Vice President and Head of Sales for the newly formed Retina Division of Novartis Ophthalmology, where he oversaw the development of the division's sales infrastructure, spearheaded the launch of BEOVU®, and expanded the entire retina and ophthalmology product pipeline, generating over \$1 billion in revenues in 2020. DiPasquale's extensive experience also includes executive leadership positions at Bausch + Lomb as Vice President of Sales for the U.S. Vision Care business, at Zeiss Vision Care as Senior Vice President, with responsibility for profit and loss for its eyecare professional practice and the management of multiple lab operations and sales personnel throughout the U.S., and at Essilor USA. DiPasquale holds a Bachelor's in Business Administration (BBA) from Ohio University and an Executive MBA from Kent State University. DiPasquale will be based in Harrow's Nashville, Tennessee, corporate headquarters.

Commenting on DiPasquale's addition to the Harrow team, Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said, "Over the last 16 years of Greg's remarkable career, he has delivered outstanding economic and commercial results, playing a pivotal role in commercializing several highly successful ophthalmic pharmaceutical products. We are particularly excited about Greg's experience and proven success serving the buy-and-bill, retina, and optometric markets given our recent launches of IHEEZO® and our plans to re-launch TRIESENCE® – products with large retina market opportunities – and our strong launch of VEVEYE®, which has been so positively embraced by the medical optometric market as well as by ophthalmologists across the country. We are confident that Greg's strategic acumen and track record of expanding major ophthalmic pharmaceutical franchises will prove invaluable to our success as we continue to leverage our branded product portfolio and execute our strategic plan to position Harrow as a leader in the North American ophthalmic pharmaceutical market."

DiPasquale added, "I am exceedingly enthusiastic about joining Harrow, a dynamic, visionary, and service-oriented company committed to enhancing patient access to critical eyecare medications. Leaders in eyecare have watched with admiration as Harrow has evolved into a significant strategic player in the ophthalmic pharmaceutical industry, starting from scratch with its ImprimisRx franchise and subsequently acquiring 18 branded products over the past two years. I look forward to utilizing the knowledge and experience gained throughout my 30+ year career to advance Harrow's broad array of branded products, including, among others, IHEEZO, VEVEYE, and soon TRIESENCE, and to working with the talented and dedicated Harrow team to take our company to the next level."

### About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit [harrow.com](https://www.harrow.com).

### Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative

arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at [sec.gov](https://www.sec.gov). Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240513390675/en/): <https://www.businesswire.com/news/home/20240513390675/en/>

Jamie Webb, Director of Communications and Investor Relations

[jwebb@harrowinc.com](mailto:jwebb@harrowinc.com)

615-733-4737

Source: Harrow, Inc.